JP2020523381A5 - - Google Patents

Download PDF

Info

Publication number
JP2020523381A5
JP2020523381A5 JP2019569336A JP2019569336A JP2020523381A5 JP 2020523381 A5 JP2020523381 A5 JP 2020523381A5 JP 2019569336 A JP2019569336 A JP 2019569336A JP 2019569336 A JP2019569336 A JP 2019569336A JP 2020523381 A5 JP2020523381 A5 JP 2020523381A5
Authority
JP
Japan
Prior art keywords
compound
formula
protecting group
nuc
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019569336A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020523381A (ja
JP7248209B2 (ja
Filing date
Publication date
Priority claimed from GBGB1709471.5A external-priority patent/GB201709471D0/en
Application filed filed Critical
Publication of JP2020523381A publication Critical patent/JP2020523381A/ja
Publication of JP2020523381A5 publication Critical patent/JP2020523381A5/ja
Application granted granted Critical
Publication of JP7248209B2 publication Critical patent/JP7248209B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019569336A 2017-06-14 2018-06-14 3’-デオキシアデノシン-5’-o-[フェニル(ベンジルオシキ-l-アラニニル)]ホスフェート(nuc-7738)の合成 Active JP7248209B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1709471.5 2017-06-14
GBGB1709471.5A GB201709471D0 (en) 2017-06-14 2017-06-14 Diastereoselective synthesis of hosphate derivatives
PCT/GB2018/051641 WO2018229495A1 (en) 2017-06-14 2018-06-14 Synthesis of 3'-deoxyadenosine-5'-0-[phenyl(benzyloxy-l-alaninyl)]phosphate (nuc-7738)

Publications (3)

Publication Number Publication Date
JP2020523381A JP2020523381A (ja) 2020-08-06
JP2020523381A5 true JP2020523381A5 (enExample) 2021-07-26
JP7248209B2 JP7248209B2 (ja) 2023-03-29

Family

ID=59358400

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2019569336A Active JP7248209B2 (ja) 2017-06-14 2018-06-14 3’-デオキシアデノシン-5’-o-[フェニル(ベンジルオシキ-l-アラニニル)]ホスフェート(nuc-7738)の合成
JP2019569286A Active JP7279991B2 (ja) 2017-06-14 2018-06-14 ホスフェート誘導体の合成
JP2023076006A Active JP7525687B2 (ja) 2017-06-14 2023-05-02 ホスフェート誘導体の合成
JP2024114519A Pending JP2024138523A (ja) 2017-06-14 2024-07-18 ホスフェート誘導体の合成
JP2025266864A Pending JP2026034703A (ja) 2017-06-14 2025-12-19 ホスフェート誘導体の合成

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019569286A Active JP7279991B2 (ja) 2017-06-14 2018-06-14 ホスフェート誘導体の合成
JP2023076006A Active JP7525687B2 (ja) 2017-06-14 2023-05-02 ホスフェート誘導体の合成
JP2024114519A Pending JP2024138523A (ja) 2017-06-14 2024-07-18 ホスフェート誘導体の合成
JP2025266864A Pending JP2026034703A (ja) 2017-06-14 2025-12-19 ホスフェート誘導体の合成

Country Status (21)

Country Link
US (4) US11897913B2 (enExample)
EP (3) EP3638684B1 (enExample)
JP (5) JP7248209B2 (enExample)
KR (2) KR102695300B1 (enExample)
CN (3) CN117486959A (enExample)
AU (3) AU2018284131B2 (enExample)
BR (1) BR112019026747A2 (enExample)
CA (2) CA3065682A1 (enExample)
CL (1) CL2019003632A1 (enExample)
EA (1) EA201992873A1 (enExample)
ES (1) ES3075652T3 (enExample)
GB (1) GB201709471D0 (enExample)
IL (3) IL302559B2 (enExample)
MA (1) MA49379A (enExample)
MX (3) MX390901B (enExample)
NZ (2) NZ759692A (enExample)
PH (1) PH12019502825A1 (enExample)
SA (1) SA519410795B1 (enExample)
SG (1) SG11201911543UA (enExample)
WO (2) WO2018229493A2 (enExample)
ZA (1) ZA201908054B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2569185T3 (es) 2011-03-01 2016-05-09 Nucana Biomed Limited Derivados de fosforamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento del cáncer
EA033046B1 (ru) 2014-06-25 2019-08-30 НУКАНА ПиЭлСи Состав, содержащий пролекарство гемцитабина
HRP20191461T1 (hr) 2014-11-28 2019-11-15 NuCana plc Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja
CA3007347C (en) 2015-12-11 2020-08-04 NuCana plc Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
CN112409421A (zh) * 2020-12-01 2021-02-26 上海兆维科技发展有限公司 一种3’-磷酸酯核苷的制备方法
KR20250012582A (ko) 2022-05-12 2025-01-24 뉴카나 피엘씨 암 치료
CN120584123A (zh) 2022-12-07 2025-09-02 努卡那有限公司 核苷衍生物nuc-3373的合成

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE279248C (enExample)
US3792039A (en) 1971-12-27 1974-02-12 Miles Lab Poly 2'-fluoro-2'-deoxyuridylic acid
US4500707A (en) * 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4357324A (en) 1981-02-24 1982-11-02 The United States Of America As Represented By The Department Of Health And Human Services Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
US4668777A (en) * 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
ES2172303T3 (es) 1998-01-23 2002-09-16 Newbiotics Inc Agentes terapeuticos obtenidos por catalisis enzimatica.
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
EP1827460A4 (en) 2004-12-09 2012-03-14 Univ Minnesota NUCLEOSIDE WITH ANTIVIRAL AND ANTI-CANCER EFFECT
GB0505781D0 (en) 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
CN101287472B (zh) 2005-08-15 2011-10-12 弗·哈夫曼-拉罗切有限公司 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US7951789B2 (en) * 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090206007A1 (en) 2008-02-20 2009-08-20 Air Products And Chemicals, Inc. Process and apparatus for upgrading coal using supercritical water
BRPI1004575A2 (pt) 2009-01-09 2016-04-05 Inhibitex Inc composto, composição farmacêutica, método de tratamento de infecções virais, método de separação dos diaestereômeros de fósforo
WO2010108140A1 (en) 2009-03-20 2010-09-23 Alios Biopharma, Inc. Substituted nucleoside and nucleotide analogs
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
AP2012006535A0 (en) 2010-03-31 2012-10-31 Gilead Pharmasset Llc Stereoselective synthesis of phosphorous containing actives
TW201136945A (en) 2010-03-31 2011-11-01 Pharmasset Inc Purine nucleoside phosphoramidate
EA025311B1 (ru) 2010-07-19 2016-12-30 Гайлид Сайэнсиз, Инк. Способы получения диастереомерно чистых фосфорамидатных пролекарств
WO2012040127A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
US20120070411A1 (en) 2010-09-22 2012-03-22 Alios Biopharma, Inc. Substituted nucleotide analogs
ES2716158T3 (es) 2010-11-30 2019-06-10 Gilead Pharmasset Llc 2'-spiro-nucleótidos para el tratamiento de hepatitis C
US8772474B2 (en) 2010-12-22 2014-07-08 Alios Biopharma, Inc. Cyclic nucleotide analogs
ES2569185T3 (es) 2011-03-01 2016-05-09 Nucana Biomed Limited Derivados de fosforamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento del cáncer
US9556216B2 (en) * 2012-08-31 2017-01-31 Novartis Ag 2′-Ethynyl nucleoside derivatives for treatment of viral infections
AU2013346515B2 (en) 2012-11-16 2017-05-25 NuCana plc Process for preparing nucleoside prodrugs
ES2952714T3 (es) 2013-06-26 2023-11-03 Janssen Pharmaceuticals Inc Nucleósidos sustituidos, nucleótidos y análogos de los mismos
TW201542581A (zh) 2013-09-11 2015-11-16 艾默理大學 核苷酸與核苷治療組成物及其相關用途
CN105829333A (zh) 2013-10-11 2016-08-03 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸及其类似物
JP2017504572A (ja) 2013-11-27 2017-02-09 アイデニクス・ファーマシューティカルズ・エルエルシー 肝臓癌治療のためのヌクレオチド類
CZ307789B6 (cs) 2014-04-15 2019-05-09 Zentiva, K.S. Způsob výroby biologicky účinných fosforamidátových léčiv
EP3131914B1 (en) * 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
EA033046B1 (ru) 2014-06-25 2019-08-30 НУКАНА ПиЭлСи Состав, содержащий пролекарство гемцитабина
RS60968B1 (sr) 2014-06-25 2020-11-30 NuCana plc Prolekovi gemcitabina
US9834577B2 (en) 2014-07-22 2017-12-05 Laurus Labs Limited Process for the preparation of gemcitabine-[phenyl(benzoxy-L-alaninyl)] phosphate
EP3572410B1 (en) * 2014-08-25 2022-07-20 Medivir Aktiebolag Dioxolane analogues of uridine for the treatment of cancer
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
CN105646629A (zh) 2014-11-25 2016-06-08 广州市恒诺康医药科技有限公司 L-核苷类化合物及其应用
HRP20191461T1 (hr) 2014-11-28 2019-11-15 NuCana plc Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja
WO2016098123A2 (en) * 2014-12-16 2016-06-23 Laurus Labs Private Ltd A recycling process for preparing (s)-2-[(substituted-phenoxy)-phenoxy- phosphorylamino] propionic acid isopropyl ester diastereomers
WO2016145142A1 (en) 2015-03-10 2016-09-15 Emory University Nucleotide and nucleoside therapeutics compositions and uses related thereto
CN107835687A (zh) 2015-05-14 2018-03-23 努卡那有限公司 癌症治疗
CN106543252A (zh) 2015-09-16 2017-03-29 博瑞生物医药(苏州)股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
CN106478753A (zh) 2015-09-16 2017-03-08 博瑞生物医药(苏州)股份有限公司 一种nuc‑1031单一异构体的制备方法和用途
CN106543220A (zh) * 2015-09-16 2017-03-29 博瑞生物医药(苏州)股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
PH12018500691B1 (en) 2015-10-05 2022-08-10 NuCana plc Combination therapy
EP3377512A4 (en) 2015-11-16 2019-09-18 Ichorion Therapeutics, Inc. Nucleic Acid PRODRUGS
CA3007347C (en) * 2015-12-11 2020-08-04 NuCana plc Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
SI3393478T1 (sl) 2015-12-23 2020-07-31 NuCana plc Kombinacijska terapija
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609602D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201713916D0 (en) 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens

Similar Documents

Publication Publication Date Title
JP6443812B2 (ja) ハリコンドリンb類縁体の合成に有用な方法
JP2022043078A5 (enExample)
JP2022031717A5 (enExample)
JP2006510719A5 (enExample)
JP2020523378A5 (enExample)
JP7248209B2 (ja) 3’-デオキシアデノシン-5’-o-[フェニル(ベンジルオシキ-l-アラニニル)]ホスフェート(nuc-7738)の合成
CN104262344A (zh) 艾德拉尼的制备方法
IS2060B (is) Aðferð til framleiðslu á hreinu sítalóprami
JP6736317B2 (ja) ロタキサン化合物
NO20070865L (no) Fremgangsmate for fremstilling av 2'-deoksy-2',2'-difluorcytidin.
FI3529234T3 (fi) Yhdiste, menetelmä yhdisteen saamiseksi, faramseuttinen koostumus, yhdisteiden käyttö ja menetelmä psykiatristen häiriöiden ja/tai unihäiriöiden hoitoon
WO2020010560A1 (zh) 一种亚磷酰胺类化合物、其制备方法及应用
DE602004009943D1 (de) 9,10-alpha,alpha-oh-taxananaloga und verfahren zu deren herstellung
JP2021503522A5 (enExample)
JP2011526896A5 (enExample)
JP2004531527A5 (enExample)
JP2013534911A5 (enExample)
JP2005536559A5 (enExample)
JP4373342B2 (ja) スピロフルオレノールの製造方法
WO2007049295B1 (en) An improved one pot process for making key intermediate for gemcitabine hcl
CA2281104A1 (en) Selective epoxidation process for preparing pharmaceutical compounds
KR20260069792A (ko) 시클릭 디뉴클레오티드의 제조 방법
CN105384668A (zh) 用于制备醚化合物的方法
HUE035517T2 (en) Process for the preparation of a pyridazine compound
KR102665917B1 (ko) (e)-(2-(클로로메틸)-3-플루오로알릴)카바메이트 화합물의 제조방법